Swiss National Bank Raises Position in ICU Medical, Inc. (NASDAQ:ICUI)

Swiss National Bank boosted its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 5.6% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 45,219 shares of the medical instruments supplier’s stock after buying an additional 2,400 shares during the period. Swiss National Bank’s holdings in ICU Medical were worth $8,240,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Russell Investments Group Ltd. boosted its position in shares of ICU Medical by 46.4% during the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 173 shares during the last quarter. Vanguard Group Inc. lifted its position in ICU Medical by 0.5% during the first quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock valued at $263,226,000 after purchasing an additional 11,991 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its stake in ICU Medical by 1.7% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 20,505 shares of the medical instruments supplier’s stock worth $2,201,000 after buying an additional 343 shares in the last quarter. EntryPoint Capital LLC increased its holdings in shares of ICU Medical by 731.5% in the 1st quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock worth $48,000 after buying an additional 395 shares during the last quarter. Finally, Jane Street Group LLC raised its position in shares of ICU Medical by 79.7% during the 1st quarter. Jane Street Group LLC now owns 89,852 shares of the medical instruments supplier’s stock valued at $9,643,000 after buying an additional 39,839 shares in the last quarter. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ICUI shares. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. Jefferies Financial Group started coverage on ICU Medical in a research note on Monday, October 14th. They set a “hold” rating and a $183.00 price target for the company. Raymond James increased their price objective on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, KeyCorp increased their price target on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, November 13th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $173.00.

ICU Medical Trading Down 0.4 %

NASDAQ ICUI opened at $167.81 on Tuesday. The firm has a market cap of $4.11 billion, a PE ratio of -36.72 and a beta of 0.66. ICU Medical, Inc. has a 1-year low of $83.26 and a 1-year high of $196.26. The stock has a 50-day moving average of $175.98 and a 200-day moving average of $146.15. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75.

Insiders Place Their Bets

In related news, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the transaction, the vice president now directly owns 13,107 shares of the company’s stock, valued at $2,139,324.54. The trade was a 16.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Vivek Jain sold 12,000 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $18,665,666.78. The trade was a 10.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,502 shares of company stock valued at $6,573,496 in the last ninety days. Company insiders own 6.70% of the company’s stock.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.